Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology

BACKGROUND: There is urgent need for new medications for psychiatric disorders. Mental illness is expected to become the leading cause of disability worldwide by 2030. Yet, the last two decades have seen the pharmaceutical industry withdraw from psychiatric drug discovery after costly late-stage tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tricklebank, Mark David, Robbins, Trevor W., Simmons, Camilla, Wong, Erik H. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945970/
https://www.ncbi.nlm.nih.gov/pubmed/33694032
http://dx.doi.org/10.1007/s00213-021-05787-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945970/
https://www.ncbi.nlm.nih.gov/pubmed/33694032
http://dx.doi.org/10.1007/s00213-021-05787-x

Ejemplares similares